v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Apr. 30, 2026
Apr. 30, 2025
Apr. 30, 2026
Apr. 30, 2025
Income Statement [Abstract]        
Revenues (includes sales to related parties of approximately $30,000, $43,000, $30,000, and $75,000, respectively) $ 2,581,000 $ 1,149,000 $ 4,027,000 $ 2,239,000
Cost of revenues 526,000 256,000 807,000 447,000
Gross profit 2,055,000 893,000 3,220,000 1,792,000
General and administrative expenses 2,567,000 2,287,000 4,610,000 4,439,000
Loss from operations (512,000) (1,394,000) (1,390,000) (2,647,000)
Other income (expense)        
Gain on sale of Exotropin interests 390,000 390,000
Interest expense (11,000) (21,000) (20,000) (43,000)
Change in obligation to repurchase shares (17,000) 2,000
Other income 5,000 24,000 21,000 56,000
Net loss $ (145,000) $ (1,391,000) $ (997,000) $ (2,634,000)
Net loss per common share - basic $ (0.02) $ (0.22) $ (0.14) $ (0.42)
Net loss per common share - diluted $ (0.02) $ (0.22) $ (0.14) $ (0.42)
Weighted average number of common shares outstanding - basic 7,757,469 6,344,817 7,383,436 6,344,817
Weighted average number of common shares outstanding - diluted 7,757,469 6,344,817 7,383,436 6,344,817